AU2016270658B2 - Cerdulatinib for the treatment of B-cell malignancies - Google Patents

Cerdulatinib for the treatment of B-cell malignancies Download PDF

Info

Publication number
AU2016270658B2
AU2016270658B2 AU2016270658A AU2016270658A AU2016270658B2 AU 2016270658 B2 AU2016270658 B2 AU 2016270658B2 AU 2016270658 A AU2016270658 A AU 2016270658A AU 2016270658 A AU2016270658 A AU 2016270658A AU 2016270658 B2 AU2016270658 B2 AU 2016270658B2
Authority
AU
Australia
Prior art keywords
cerdulatinib
patient
pharmaceutically acceptable
effective amount
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016270658A
Other languages
English (en)
Other versions
AU2016270658A1 (en
Inventor
Gregory COFFEY
Janet Leeds
Anjali Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2016270658A1 publication Critical patent/AU2016270658A1/en
Application granted granted Critical
Publication of AU2016270658B2 publication Critical patent/AU2016270658B2/en
Assigned to ALEXION PHARMACEUTICALS, INC. reassignment ALEXION PHARMACEUTICALS, INC. Request for Assignment Assignors: PORTOLA PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016270658A 2015-05-29 2016-05-27 Cerdulatinib for the treatment of B-cell malignancies Active AU2016270658B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168530P 2015-05-29 2015-05-29
US62/168,530 2015-05-29
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
PCT/US2016/034861 WO2016196385A1 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Publications (2)

Publication Number Publication Date
AU2016270658A1 AU2016270658A1 (en) 2018-01-04
AU2016270658B2 true AU2016270658B2 (en) 2021-08-12

Family

ID=57441822

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016270658A Active AU2016270658B2 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of B-cell malignancies

Country Status (9)

Country Link
US (2) US20180147203A1 (https=)
EP (1) EP3302485B1 (https=)
JP (2) JP7258462B2 (https=)
KR (1) KR102613106B1 (https=)
CN (1) CN107683139A (https=)
AU (1) AU2016270658B2 (https=)
CA (1) CA2987324C (https=)
ES (1) ES2958412T3 (https=)
WO (1) WO2016196385A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
CA3098012A1 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Methods for treating lymphoma
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
TWI805751B (zh) 2018-05-04 2023-06-21 美商普托拉製藥有限公司 賽度替尼(cerdulatinib)之合成
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
US20230181581A1 (en) * 2020-05-26 2023-06-15 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018567A1 (en) * 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
HRP20161310T1 (hr) 2008-04-16 2016-12-02 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
EP2621489A1 (en) 2010-09-30 2013-08-07 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
JP2015522091A (ja) 2012-06-27 2015-08-03 ノボマー， インコーポレイテッド ポリエステル生成のための触媒および方法
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
CN105282602A (zh) * 2014-07-07 2016-01-27 乐视致新电子科技（天津）有限公司 数据处理方法、装置及移动终端设备
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018567A1 (en) * 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSS ET AL., "Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis". CLIN CANCER RES., (2007-08-15), Vol 13, no. 16, pages 4777-4785 *

Also Published As

Publication number Publication date
EP3302485B1 (en) 2023-07-12
KR102613106B1 (ko) 2023-12-12
EP3302485A4 (en) 2019-02-27
CA2987324A1 (en) 2016-12-08
ES2958412T3 (es) 2024-02-08
CN107683139A (zh) 2018-02-09
US20180147203A1 (en) 2018-05-31
JP2021152076A (ja) 2021-09-30
EP3302485A1 (en) 2018-04-11
JP2018520117A (ja) 2018-07-26
JP7258462B2 (ja) 2023-04-17
CA2987324C (en) 2023-08-22
US12350269B2 (en) 2025-07-08
KR20180011210A (ko) 2018-01-31
WO2016196385A1 (en) 2016-12-08
AU2016270658A1 (en) 2018-01-04
US20220096471A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
US12350269B2 (en) Cerdulatinib for the treatment of b-cell malignancies
US11446300B2 (en) Cerdulatinib for treating hematological cancers
US20220226336A1 (en) Combination therapy for treating cancer
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
KR20180101603A (ko) 코판리십 바이오마커
KR20180104129A (ko) 코판리십 바이오마커
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK40000537A (en) Copanlisib biomarkers
HK1229709B (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALEXION PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): PORTOLA PHARMACEUTICALS, INC.